Abstract
Nineteen young human immunodeficiency virus-infected patients were randomized to receive 400 mg of oral diethyldithiocarbamate (DTC) per m2 or placebo weekly for 12 weeks. Changes in blood CD4+ lymphocytes were not significantly different between groups. However, neutrophil, monocyte, and platelet counts consistently decreased during DTC treatment, suggesting DTC- mediated myelosuppression.
Original language | English (US) |
---|---|
Pages (from-to) | 1644-1646 |
Number of pages | 3 |
Journal | Antimicrobial agents and chemotherapy |
Volume | 38 |
Issue number | 7 |
DOIs |
|
State | Published - 1994 |
Externally published | Yes |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases